Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00303290 · ClinicalTrials.gov registry record · Phase 1
PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML
A Phase 1 study of Chronic Myeloid Leukemia, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
- 1
- Study location
NCT00303290 is a Phase 1 study of Chronic Myeloid Leukemia that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 76 participants, below the 208-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00303290, a Phase 1 study of Chronic Myeloid Leukemia, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to see if a new interferon which is given only once a week with ARA-C works as well as standard interferon and low dose ARA-C. The safety of this treatment will also be studied.
Conditions Studied
Interventions
- DRUG Peg Interferon Alpha 2b (Peg Intron)
- DRUG Ara-C (cytosine arabinoside)
Study Locations (1)
Texas
- The University of Texas M.D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2000-01 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00303290
The ClinicalTrials.gov registry entry for NCT00303290 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 208-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (63% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Peg Interferon Alpha 2b (Peg Intron) is the first listed.
NCT00303290 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00303290 about?
NCT00303290 is a clinical study titled "PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML". The goal of this clinical research study is to see if a new interferon which is given only once a week with ARA-C works as well as standard interferon and low dose ARA-C. The safety of this treatment will also be studied.
What is the current status of trial NCT00303290?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2000-01. Estimated completion is 2014-11.
What conditions does trial NCT00303290 study?
This clinical trial studies the following conditions: Chronic Myeloid Leukemia.
What interventions are being tested in trial NCT00303290?
The interventions under investigation include: Peg Interferon Alpha 2b (Peg Intron) (DRUG), Ara-C (cytosine arabinoside) (DRUG).
Who is sponsoring clinical trial NCT00303290?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00303290 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
RECRUITING · Phase 1
-
KRT-232 and TKI Study in Chronic Myeloid Leukemia
RECRUITING · Phase 1
-
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
RECRUITING · Phase 1
-
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
RECRUITING · Phase 1
-
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
RECRUITING · Phase 1
-
A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.